Informal meeting of health ministers in Vienna, Austria: - extracts from the press conference by Beate HARTINGER-KLEIN, Austrian Federal Minister of Labour, Social Affairs, Health and Consumer Protection, and Vytenis ANDRIUKAITIS, Member of the EC i
On Tuesday the 11th of September, the informal meeting of Health Ministers has taken place in Vienna. The Federal Minister has presented a wide range of topics for discussion related to regulatory requirements for medicinal products.Among other things, Hartinger-Klein identified potential for improvement in the structured exchange of information between regulatory authorities responsible for drug approval and other stakeholders in the healthcare system. This relates, for instance, to mechanisms that enable payers to adapt as early as possible to the development of new product groups and products and to plan appropriately.
Only the original language version is authentic and it prevails in the event of its differing from the translated versions.
||Arrival of the speakers in the press room
||Soundbite (In GERMAN) by Beate Hartinger-Klein, Austrian Federal Minister of Labour, Social Affairs, Health and Consumer Protection saying that it is important to cooperate and optimize cooperation with the European approval authorities to ensure a free flow of information between these authorities and other stakeholders as part of the public healthcare system. In this way, they have to ensure that the cooperation is as smooth and efficient as possible so that national authorities will have access to information they need. For example, it has to be possible to have influence as early as possible and be ready for new technologies so that they can plan and take the necessary precautions and measures.
||Soundbite (In GERMAN) by Beate Hartinger-Klein saying that another issue they discussed during their meeting in connection with rare diseases is approval of medicine known as orphan medicines and in particular where they relate to R&D for rare diseases. They have to ensure that incentives for such R&D need to be provided by the public hand and need to be done in line with the needs of society. Here the European Commission has conducted a broad evaluation of the current rules with a view to possible proposals for improvements.
||Soundbite (In ENGLISH) by Vytenis Andriukaitis, Member of the EC in charge of Health and Food Safety saying that: We must all work hard to ensure that citizens have the right to timely access to innovative, affordable, preventive and creative healthcare of good quality. This is an issue of social responsibility for all of us. Many member states agree on the need to find solutions to overcome the information gap of payers which put them in a difficult position when it comes to decisions on pricing and reimbursement of medicines.
||Soundbite (In ENGLISH) by Vytenis Andriukaitis saying that: The Commission has already been supporting the work of several groups and mechanism bringing together all authorities involved to improve their cooperation, synergies and efficiencies. Some member states also voiced concerns of the lack of information on R&D cost as well as the amount of public money spent on the development of new medicines and show interest to cooperation on these aspects as suggested by the Presidency.
||Soundbite (In ENGLISH) by Vytenis Andriukaitis saying that: The E-heath network is playing an essential role in coordinating the implementation of the e-health digital service infrastructure whereby the first member states are expected to start the cross border exchange of e-prescriptions and patient summaries beginning of next year but we must also accept that many of the current e-health solutions are out of date. The Commission and member states are aware of the need to improve interoperability to allow our health system to speak to each other.
||Speakers leaving the press room